Susan Hungness, MD
Allergy & Immunology · Charlotte, NCNPI 1477672145
Payments from drug & device makers
Across 690 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$1K
- Novartis$1K
- Optinose US, Inc.$1K
- Sanofi$1K
- plus $8K from 33 others
What the payments were for
- Consulting fees$911%
- Food & beverage$16,67099%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 128 | $3,223 |
| Regeneron Healthcare Solutions, Inc. | 55 | $1,433 |
| GSK | 73 | $1,164 |
| Novartis | 39 | $1,068 |
| Optinose US, Inc. | 39 | $1,055 |
| Sanofi | 38 | $1,029 |
| Pfizer | 49 | $844 |
| Amgen(2 entities) | 34 | $788 |
| Alk-abello, Inc | 23 | $757 |
| ARS Pharmaceuticals Operations, Inc. | 26 | $704 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $540 |
| CSL Behring | 23 | $481 |
| Biocryst US Sales Co., LLC | 18 | $480 |
| Kaleo, Inc. | 25 | $432 |
| Regeneron | 3 | $362 |
| Genentech USA, Inc. | 14 | $357 |
| Pharming Healthcare, Inc. | 8 | $258 |
| Organon | 3 | $214 |
| Octapharma USA, Inc. | 8 | $200 |
| Galderma Laboratories, L.p. | 9 | $169 |
| Grifols USA, LLC | 8 | $156 |
| Incyte Corporation | 7 | $139 |
| LEO Pharma Inc. | 1 | $125 |
| Hikma Pharmaceuticals USA | 5 | $104 |
| Circassia Inc. | 1 | $98 |
| ADMA Biomanufacturing LLC | 5 | $91 |
| Boehringer Ingelheim | 5 | $89 |
| Phadia US Inc. | 1 | $83 |
| Ionis Pharmaceuticals, Inc. | 3 | $76 |
| GC Biopharma USA, Inc. | 2 | $48 |
| AbbVie | 2 | $37 |
| Philips North America LLC | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Shire North American Group Inc | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$712
- XOLAIR$387
- TEZSPIRE$378
- Xhance$342
- NEFFY$248
- NUCALA$239
- ADBRY$125
- VTAMA$122
- FASENRA$122
- EUCRISA$120
- Rhapsido$120
- WAYRILZ$112
- PRE-PEN$109
- Histatrol (histamine phosphate)$109
- Timothy Grass (phleum pratense)$109
- Dust mite (D. farinae)$109
- Alternaria alternate (Alternaria tenuis)$109
- RUCONEST$109
How this compares
$16,788 in reported general payments places this provider in the 75th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 56 | $164,846 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 23 | $128,860 |
| Dupixent PenDupilumab | 29 | $126,523 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $33,392 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $18,547 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,747 |
| Arnuity ElliptaFluticasone Furoate | 22 | $10,148 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $7,525 |
| Azelastine Hcl | 181 | $6,837 |
| Epinephrine | 39 | $6,615 |
| DuleraMometasone/Formoterol | 16 | $5,609 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $5,322 |
| Mometasone Furoate | 46 | $4,042 |
| GrastekGrass Pollen-Timothy, Standard | 11 | $3,753 |
| Ipratropium Bromide | 84 | $2,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $481 | $128,86023 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,164 | $62,08791 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,223 | $21,27249 claims |
| Hikma Pharmaceuticals USAEpinephrine | $104 | $6,61539 claims |
| Alk-abello, IncGrastek | $757 | $3,75311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Charlotte
- Maeve OconnorCharlotte$2.2M
- Roopen PatelCharlotte$391K
- John NorrisCharlotte$198K
- Jennifer CaicedoCharlotte$174K
- Vandana PatelCharlotte$105K
- Richard CollinsCharlotte$28K
- Shannon ChadhaCharlotte$22K
- Emily LangleyCharlotte$21K
- Bailee GilchristCharlotte$20K
- Michael LapuenteCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.